FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130651738> ?p ?o ?g. }

• W2130651738 endingPage "533" @default.
• W2130651738 startingPage "533" @default.
• W2130651738 abstract "Correspondence: Gianluigi Ferretti, M.D., Ph.D., Department of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. Telephone: 011390652665354; Fax: 011390652665637; e-mail: gia.fer@flashnet.it Received February 1, 2006; accepted for publication March 16, 2006. ©AlphaMed Press 1083-7159/2006/$20.00/0 Concerning the controversies in the use of trastuzumab for early-stage breast cancer, Cianfrocca and Gradishar [1] have recently reported that an unplanned interim analysis of the North Central Cancer Treatment Group N9831 trial revealed a 36% relative reduction in the risk for recurrence for concurrent compared with sequential trastuzumab (p = .0114) [2], even though further follow-up is needed to ascertain whether this trend continues. Romond et al. [3] have recently presented the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. The authors conclude that trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. In trial B-31, 805 patients received doxorubicin and cyclophosphamide every 21 days for four cycles followed by paclitaxel every 3 weeks for four cycles plus weekly trastuzumab for 52 weeks; in only 59 patients, paclitaxel was given weekly for 12 weeks. In trial N9831, 808 patients were administered doxorubicin and cyclophosphamide as in trial B-31 but followed by 12 weekly doses of paclitaxel plus weekly trastuzumab for 52 weeks. It might be highlighted that exposure to lower and more frequent doses of paclitaxel could potentially exploit antiangiogenic and proapoptotic effects [4]. In metastatic breast cancer, weekly administration of paclitaxel has been reported to be superior to once-every-3-weeks administration [5]. As primary systemic chemotherapy, weekly paclitaxel, compared with once-every-3-weeks administration, improved the likelihood of pathologic complete remission [6]. By contrast, Romond et al. [3] assert that there was no evidence that the benefit of trastuzumab differed significantly between the B-31 and N9831 trials. The finding that the same effect of trastuzumab was observed in both the studies deserves further investigation, given the difference in the paclitaxel schedule." @default.
• W2130651738 created "2016-06-24" @default.
• W2130651738 creator A5020732852 @default.
• W2130651738 creator A5042436465 @default.
• W2130651738 creator A5045496715 @default.
• W2130651738 creator A5061240925 @default.
• W2130651738 creator A5080823945 @default.
• W2130651738 creator A5086199413 @default.
• W2130651738 date "2006-05-01" @default.
• W2130651738 modified "2023-09-25" @default.
• W2130651738 title "Trastuzumab Combined with Paclitaxel after Doxorubicin and Cyclophosphamide for Operable HER2‐Positive Breast Cancer" @default.
• W2130651738 cites W2146384083 @default.
• W2130651738 cites W2153119559 @default.
• W2130651738 cites W2155808778 @default.
• W2130651738 cites W2164340961 @default.
• W2130651738 doi "https://doi.org/10.1634/theoncologist.11-5-533" @default.
• W2130651738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16720857" @default.
• W2130651738 hasPublicationYear "2006" @default.
• W2130651738 type Work @default.
• W2130651738 sameAs 2130651738 @default.
• W2130651738 citedByCount "1" @default.
• W2130651738 crossrefType "journal-article" @default.
• W2130651738 hasAuthorship W2130651738A5020732852 @default.
• W2130651738 hasAuthorship W2130651738A5042436465 @default.
• W2130651738 hasAuthorship W2130651738A5045496715 @default.
• W2130651738 hasAuthorship W2130651738A5061240925 @default.
• W2130651738 hasAuthorship W2130651738A5080823945 @default.
• W2130651738 hasAuthorship W2130651738A5086199413 @default.
• W2130651738 hasBestOaLocation W21306517381 @default.
• W2130651738 hasConcept C121608353 @default.
• W2130651738 hasConcept C126322002 @default.
• W2130651738 hasConcept C143998085 @default.
• W2130651738 hasConcept C2776694085 @default.
• W2130651738 hasConcept C2776755627 @default.
• W2130651738 hasConcept C2777292972 @default.
• W2130651738 hasConcept C2779786085 @default.
• W2130651738 hasConcept C2781303535 @default.
• W2130651738 hasConcept C530470458 @default.
• W2130651738 hasConcept C71924100 @default.
• W2130651738 hasConceptScore W2130651738C121608353 @default.
• W2130651738 hasConceptScore W2130651738C126322002 @default.
• W2130651738 hasConceptScore W2130651738C143998085 @default.
• W2130651738 hasConceptScore W2130651738C2776694085 @default.
• W2130651738 hasConceptScore W2130651738C2776755627 @default.
• W2130651738 hasConceptScore W2130651738C2777292972 @default.
• W2130651738 hasConceptScore W2130651738C2779786085 @default.
• W2130651738 hasConceptScore W2130651738C2781303535 @default.
• W2130651738 hasConceptScore W2130651738C530470458 @default.
• W2130651738 hasConceptScore W2130651738C71924100 @default.
• W2130651738 hasIssue "5" @default.
• W2130651738 hasLocation W21306517381 @default.
• W2130651738 hasLocation W21306517382 @default.
• W2130651738 hasOpenAccess W2130651738 @default.
• W2130651738 hasPrimaryLocation W21306517381 @default.
• W2130651738 hasRelatedWork W1973590049 @default.
• W2130651738 hasRelatedWork W1974720482 @default.
• W2130651738 hasRelatedWork W2242326692 @default.
• W2130651738 hasRelatedWork W2339371206 @default.
• W2130651738 hasRelatedWork W2377079174 @default.
• W2130651738 hasRelatedWork W2394251095 @default.
• W2130651738 hasRelatedWork W2624925742 @default.
• W2130651738 hasRelatedWork W2969515167 @default.
• W2130651738 hasRelatedWork W4249369842 @default.
• W2130651738 hasRelatedWork W4300630264 @default.
• W2130651738 hasVolume "11" @default.
• W2130651738 isParatext "false" @default.
• W2130651738 isRetracted "false" @default.
• W2130651738 magId "2130651738" @default.
• W2130651738 workType "article" @default.